Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Leases (2019 - 2025)

Crinetics Pharmaceuticals (CRNX) has 7 years of Operating Leases data on record, last reported at $42.1 million in Q4 2025.

  • For Q4 2025, Operating Leases fell 5.65% year-over-year to $42.1 million; the TTM value through Dec 2025 reached $42.1 million, down 5.65%, while the annual FY2025 figure was $42.1 million, 5.65% down from the prior year.
  • Operating Leases reached $42.1 million in Q4 2025 per CRNX's latest filing, down from $49.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $49.1 million in Q3 2025 and bottomed at $1.5 million in Q2 2023.
  • Average Operating Leases over 5 years is $24.2 million, with a median of $22.9 million recorded in 2021.
  • Peak YoY movement for Operating Leases: tumbled 43.24% in 2023, then surged 3050.62% in 2024.
  • A 5-year view of Operating Leases shows it stood at $3.1 million in 2021, then plummeted by 34.16% to $2.0 million in 2022, then soared by 2249.56% to $47.6 million in 2023, then fell by 6.28% to $44.6 million in 2024, then dropped by 5.65% to $42.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $42.1 million in Q4 2025, $49.1 million in Q3 2025, and $43.3 million in Q2 2025.